A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia

Transfusion

Volumn 53, Issue 9, 2013, Pages 2043-2052

  Johansson, Pär I ^a   Simonsen, Anne Catrine ^a   Brown, Peter N ^a   Ostrowski, Sisse R ^a   Deberdt, Liesbeth ^a   Van Hoydonck, Pascale ^a   Yonemura, Susan S ^a   Goodrich, Raymond P ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOFLAVIN;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HEMOSTASIS; HUMAN; MALE; PATHOGENESIS; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; STANDARD; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOELASTOGRAPHY; ULTRAVIOLET RADIATION;

ADULT; AGED; BLOOD PLATELETS; CROSS-OVER STUDIES; FEMALE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PLATELET TRANSFUSION; THROMBOCYTOPENIA;

EID: 84883867685     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12055     Document Type: Article

References (48)

1. Blajchman MA, Slichter SJ, Heddle NM, Murphy MF,. New strategies for the optimal use of platelet transfusions. ASH Educ Program Book 2008; 198-204.
2. Sensebe L, Giraudeau B, Bardiaux L, Deconinck E, Schmidt A, Bidet ML, LeNiger C, Hardy E, Babault C, Senecal D,. The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. Blood 2005; 105: 862-864.
3. Lindholm PF, Annen K, Ramsey G,. Approaches to minimize infection risk in blood banking and transfusion practice. Infect Disord Drug Targets 2011; 11: 45-56.
4. Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, Dodd RY,. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49: 1S-29S.
5. Marschner S, Fast LD, Baldwin WM III, Slichter SJ, Goodrich RP,. White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion 2010; 50: 2489-2498.
6. Kumar V, Lockerble O, Kell SD, Ruane PH, Platz MS, Martin CB, Ravanat JL, Cadet J, Goodrich RP,. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004; 80: 15-21.
7. Wu YY, Snyder EL,. Safety of the blood supply: role of pathogen reduction. Blood Rev 2003; 17: 111-122.
8. Goodrich RP,. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 2000; 78 Suppl 2: 211-215.
9. Halwer M,. The photochemistry of riboflavin and related compounds. J Am Chem Soc 1951; 73: 4870-4874.
10. Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP,. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 2008; 22: 133-153.
11. Cardo LJ, Rentas FJ, Ketchum L, Salata J, Harman R, Melvin W, Weina PJ, Mendez J, Reddy H, Goodrich R,. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang 2006; 90: 85-91.
12. Cardo LJ, Salata J, Mendez J, Reddy H, Goodrich R,. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 2007; 37: 131-137.
13. Goodrich RP, Gilmour D, Hovenga N, Keil SD,. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009; 49: 1205-1216.
14. Marschner S, Goodrich R,. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011; 38: 8-18.
15. Rentas F, Harman R, Gomez C, Salata J, Childs J, Silva T, Lippert L, Montgomery J, Richards A, Chan C, Jiang J, Reddy H, Li J, Goodrich R,. Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model. Transfusion 2007; 47: 240-247.
16. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP,. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877-885.
17. Fast LD, DiLeone G, Li J, Goodrich R,. Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006; 46: 642-648.
18. Fast LD, DiLeone G, Marschner S,. Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. Transfusion 2011; 51: 1397-1404.
19. Goodrich RP, Edrich RA, Li J, Seghatchian J,. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006; 35: 5-17.
20. Li J, de Korte D, Woolum MD, Ruane PH, Keil SD, Lockerbie O, McLean R, Goodrich RP,. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004; 87: 82-90.
21. Li J, Lockerbie O, de, Korte D, Rice J, McLean R, Goodrich RP,. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion 2005; 45: 920-926.
22. Ostrowski SR, Bochsen L, Salado-Jimena JA, Ullum H, Reynaerts I, Goodrich RP, Johansson PI,. In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2010; 50: 2210-2219.
23. Picker SM, Schneider V, Oustianskaia L, Gathof BS,. Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies. Transfusion 2009; 49: 2311-2318.
24. Picker SM, Steisel A, Gathof BS,. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: results of a three-arm in vitro study. Transfus Apher Sci 2009; 40: 79-85.
25. Galan AM, Lozano M, Molina P, Navalon F, Marschner S, Goodrich R, Escolar GS,. Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function. Transfusion 2011; 51: 808-815.
26. Perez-Pujol S, Tonda R, Lozano M, Fuste B, Lopez-Vilchez I, Galan AM, Li J, Goodrich R, Escolar G,. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005; 45: 911-919.
27. Picker SM, Steisel A, Gathof BS,. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 2008; 48: 1685-1692.
28. Picker SM, Oustianskaia L, Schneider V, Gathof BS,. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction. Vox Sang 2009; 97: 26-33.
29. Picker SM, Schneider V, Gathof BS,. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies. Transfusion 2009; 49: 1224-1232.
30. Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Ad H,. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 2006; 90: 279-285.
31. Monroe DM, Hoffman M, Roberts HR,. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381-1389.
32. Mallett SV, Cox DJ,. Thrombelastography. Br J Anaesth 1992; 69: 307-313.
33. Bolliger D, Seeberger MD, Tanaka KA,. Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev 2012; 26: 1-13.
34. Hartert H, Schaeder JA,. The physical and biological constraints of thromboelastography. Biorheology 1962; 1: 31-39.
35. Johansson P, Stissing T, Bochsen L, Ostrowski SR,. Thrombelastography and tromboelastometry in assessing coagulopathy in trauma. Scand J Trauma Resusc Emerg Med 2009; 17: 45.
36. Lang T, Johanning K, Metzler H, Piepenbrock S, Solomon C, Rahe-Meyer N, Tanaka KA,. The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesth Analg 2009; 108: 751-758.
37. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP,. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45: 1335-1341.
38. Miller AB, Hoogstraten B, Staquet M, Winkler A,. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
39. Ostrowski SR, Bochsen L, Windelov NA, Salado-Jimena JA, Reynaerts I, Goodrich RP, Johansson PI,. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2011; 51: 344-356.
40. Cazenave JP, Follea G, Bardiaux L, Boiron JM, Lafeuillade B, Debost M, Lioure B, Harousseau JL, Tabrizi R, Cahn JY, Michallet M, Ambruso D, Tissot JD, Sensebé L, Kondo T, McCullough J, Rebulla P, Escolar G, Mintz P, Heddle NM, Goodrich RP, Bruhwyler J, Le C, Cook RJ, Deberdt L, et al. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50: 2362-2375.
41. Vamvakas EC,. Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets. Transfusion 2011; 51: 1058-1071.
42. Bowbrick VA, Mikhailidis DP, Stansby G,. Influence of platelet count and activity on thromboelastography parameters. Platelets 2003; 14: 219-224.
43. Oshita K, Az-ma T, Osawa Y, Yuge O,. Quantitative measurement of thromboelastography as a function of platelet count. Anesth Analg 1999; 89: 296-299.
44. Johansson PI, Stensballe J,. Effect of haemostatic control resuscitation on mortality in massively bleeding patients: a before and after study. Vox Sang 2009; 96: 111-118.
45. Nystrup KB, Windelov NA, Thomsen AB, Johansson PI,. Reduced clot strength upon admission, evaluated by thrombelastography (TEG), in trauma patients is independently associated with increased 30-day mortality. Scand J Trauma Resusc Emerg Med 2011; 19: 1-8.
46. Apelseth TO, Bruserud O, Wentzel-Larsen T, Hervig T,. Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods. Transfusion 2010; 50: 766-775.
47. Flisberg P, Rundgren M, Engstrom M,. The effects of platelet transfusions evaluated using rotational thromboelastometry. Anesth Analg 2009; 108: 1430-1432.
48. Diedrich B, Sandgren P, Jansson B, Gulliksson H, Svensson L, Shanwell A,. In vitro and in vivo effects of potassium and magnesium on storage up to 7-days of apheresis platelet concentrates in platelet additive solution. Vox Sang 2008; 94: 96-102.